tradingkey.logo
tradingkey.logo
Search

News

MegaPro’ s MPB-1734 Expected to Seek Prostate Cancer NDA via 505(b)(2) Pathway Supported by Bioequivalence Study

Taipei, June 30, 2025 —MegaPro Biomedical Co., Ltd. (hereafter referred to as “MegaPro”, TPEx: 6827) announced that it has received a written response from the U.S. FDA regarding its novel anti-cancer formulation, MPB-1734, following a Type C meeting. The formulation is based onMegePro’s proprietary nano-micelle platform and does not contian Tween-80. Based on current nonclinical (animal) and partial human clinical data, FDA considered MPB-1734 for the treatment of prostate cancer may be eligible to use a bioequivalence (BE) study served as a scientific bridge, allowing MPB-1734 to seek regulatory approval through the 505(b)(2) NDA pathway.Dr. Yuan-Hung Hsu, President of MegaPro, explainedthat the company’s nano-micelle technology is designed to improve the solubility of poorly water-soluble hydrophobic drugs. Traditionally, these drugs use Tween-80 as a solubilizer. However, scientific studies has indicated that Tween-80 is associated with hypersensitivity reactions. For instance, the label of the marketed drug Jevtana® includes a black box warning highlighting the risk of severe allergic reactions due to its Tween-80 content,. MPB-1734, is a Tween-80 free formulation, offering improved drug stability and solubility while reducing excipient-associated risks.Based on the preclinical and early clinical pharmacokinetic data showing similarity to the reference drug, the US FDA has indicated that MPB-1734 may be eligible for the 505(b)(2) NDA pathway through a bioequivalence study.MPB-1734 is a novel formulation taegeting the current market of Jevtana®. According to Verified Market Reports, the global market size of Jevtana is USD $350 million in 2024 and projected to reach $750 million by 2033, with a compound annual growth rate (CAGR) of 9.2%,. Key drivers include increasing awareness of prostate cancer, an aging global population, earlier diagnosis, longer survival, and the need for advanced treatment. As a Tween-80 free formulation, MPB-1734 is well positioned as c competitive alternative in a growing market segment.Dr. Jassy Wang, CEO of MegaPro, added that recent market cases—such as Cinvanti (a Tween-80 free antiemetic) and BEIZRAY (Tween-80 free paclitaxel) demonstrated that new formulation without Tween-80 not only obtained regulatory approvals via bioequivalence studies but also rapidly gained market share or achieved successful out-licensing after launch. This validates MegaPro's commercial potential of its nano-micelle platform. The company aims to apply this technology to re-formulate hydrophobic drugs, thus to accelerate regulatory timeline and reach new milestone in business growth.30/06/2025 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com
EQS
Jun 30, 2025
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.